The ErbB2 Signaling Network as a Target for Breast Cancer Therapy

ISSN： 1083-3021

Source： Journal of Mammary Gland Biology and Neoplasia, Vol.11, Iss.1, 2006-01, pp. : 13-25

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

ErbB/EGF Signaling and EMT in Mammary Development and Breast Cancer

By Hardy Katharine Booth Brian Hendrix Mary Salomon David Strizzi Luigi

Journal of Mammary Gland Biology and Neoplasia, Vol. 15, Iss. 2, 2010-06 ,pp. : 191-199

Springer Publishing Company

Access to resources Recommend Favorite

Meta‐analysis reveals no significant correlation between breast cancer survival and ErbB3 expression

APMIS (ELECTRONIC), Vol. 123, Iss. 5, 2015-05 ,pp. : 383-393

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation

CANCER, Vol. 119, Iss. 16, 2013-08 ,pp. : 3043-3051

John Wiley & Sons Inc

Access to resources Recommend Favorite

Combination Therapy of Lapatinib and Capecitabine forErbB2-Positive Metastatic or Locally Advanced BreastCancer: Results from the Lapatinib Expanded AccessProgram (LEAP) in Central and Eastern Europe

Oncology Research and Treatment, Vol. 34, Iss. 5, 2011-04 ,pp. : 233-238

Karger

Access to resources Recommend Favorite

High-Throughput Tissue Microarray Analysis of erbB-2 Gene Amplification in Urinary Bladder Cancer

Urologia Internationalis, Vol. 71, Iss. 4, 2003-11 ,pp. : 408-411

Karger

Access to resources Recommend Favorite